Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude

Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 6, Abbott Laboratories (NYSE:ABT) released positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) occluder, presented at the AF Symposium in Boston.

​Atrial fibrillation is an irregular heart rhythm disease that affects millions of people worldwide and increases the risk of stroke. The device being investigated is called Amulet 360 Left Atrial Appendage (LAA) occluder, a minimally invasive catheter-based therapy.

The VERITAS Study, which presents 12-month data from 34 centers across the US, Europe, Canada, and Australia, showed top-tier performance for paroxysmal AFib and persistent AFib. The trial that enrolled 400 patients showed that after 45 days of implant, 93.9% of the patients achieved complete LAA closure. This includes a 99.8% implant success rate with no major issues recorded, including strokes, device dislodgement, brain bleeds, or surgery-needing heart damage in early follow-up. Management noted that full results for this device are expected in 2027.

​Abbott Laboratories (NYSE:ABT) is a global healthcare company that researches, develops, and manufactures medical devices, diagnostic tools, branded generic medicines, and nutritional products.

While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.